Skip to playerSkip to main content
  • 5 years ago
Both Pfizer’s Paxlovid and Merck’s molnupiravir are cleared for emergency use in non-hospitalized people who have mild-to-moderate symptoms and are at heightened risk of developing severe disease.

Recommended